Inicures founders and researchers Professor Johan Bylund at the University of Gothenburg, together with Dr. Peter Olofsson-Sahl at University West, has received support from the national drug discovery platform at Scilife LAB. The lead candidates have shown strong potential, particularly for severe infections like chronic urinary tract and lung infections.With the help of DDD, they will focus on optimizing these compounds to meet industry standards. Bringing them closer to clinical use as a much-needed alternative for life-threatening infections. The current project is going very well and we have alreday treached some very promising improved pre-CD molecules and hope to be able to nominate or CD in mid 2026.

CEO, Peter Olofsson-Sahl presented Inicure at the #BiotechHanse event as innovative Swedish Life Science innovation for Sweden-Germany collaboration and partnership opportunities

As partner to the IMPACT project led by University Southern Denmark (SDU) and professor Thomas Andersen, Inucure is partner of the granted project IMPACT ””IMproving the Pig biomedical model for ACcelerating Translational research in anti-infection drugs and prophylaxes” supported by the Danish Open Discovery Innovation Network (ODIN) that is funded by the Novo Nordisk Foundation.

The IMPACT project (2025-2028) aims to improve the outcome of preclinical trials in pigs by establishing an assay platform for monitoring disease and immunogenicity status in the pig.

Based on input from expert scientists from industry and academia, the IMPACT team will identify relevant pig biomarkers of infection and inflammation that translates to humans. This knowledge will form the basis for establishing antibody-based immunoassays and immunogenicity assays. An integral part of the project is to improve infection protocols to better mimic human infection onset and pathogenesis. The team will also establish histopathology protocols for pig bladder and kidney tissue to enhance interpretation of tissue inflammation and invasive infection.

Inicure have been granted support from VINNOVA Planeringsbidrag to improve our EIC Transition proposal. Inicure is coordinating a consortia for collaboration between LIOS, Queen Mary Hospital University London and Swansea University for a joing program to characterise and mature Inicures candidate therapies to boost the Innate immune system as novel therapy to cure resistant infections in a joint project called iCURE. The EIC Transition application will be competed and submitted in mid september 2025.

Presenting Inicure at the pitching final at the European AMR conference in Basel 25-26 February 2025 (at minute 17′ in the you tube video) for partners, collaborators and future investors.

Looking forward to meet research partners and investors at the GoWest – Nordic capital forum 29-30 January.